BioPharmCatalyst

Werewolf Therapeutics (NASDAQ: HOWL) shares closed up 103% at $0.87 after merging with Ambros Therapeutics in an all-stock deal to form Nasdaq-listed Ambros Therapeutics. The shift focuses on neridronate for CRPS-1, with Phase 3 data due in 2028, supported ...

Indaptus Therapeutics (NASDAQ: INDP) submitted a resale prospectus for approximately 58.9 million common shares on behalf of certain selling stockholders; although the filing represents a secondary distribution of existing securities rather than a primary i...

Moderna (NASDAQ: MRNA) and Merck reported that Phase 3 INTerpath-001 met RFS/DMFS endpoints in stage IIB-IV melanoma. Intismeran plus Key...

Amylyx Pharmaceuticals (NASDAQ: AMLX) reported that avexitide reached its primary FDA-agreed endpoint in the Phase 3 LUCIDITY study for post-bariatric hypoglycemia (PBH). In the trial, the GLP-1 receptor antagonist demonstrated a 55% decrease in Level 2/3 h...

Adial Pharmaceuticals (NASDAQ: ADIL) finalized its acquisition of Azora Therapeutics, pivoting its strategic priority toward AT177, a colon-targeted oral AhR agonist for ulcerative colitis, alongside securing the initial $32 million of a potential $64 milli...